PP_1170x120_10-25-21

RAND Corp.

Biosimilars could generate $38.4 billion in savings over five years

Biosimilars could generate $38.4 billion in savings over five years

NEW YORK — Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025, according to a new RAND Corporation study. More aggressive biosimilar uptake and competition

Adheris Health